A genetic algorithm to predict the risk of advanced AMD

Article

New clinical approach targeted to early detection

The discovery of genetic predictors of AMD has enabled the identification of individuals at heightened risk, laying the foundation for a new clinical approach targeted to early detection and personalized management of this disease.

AMD genetic predictive models

ARMS2 (age-related maculopathy susceptibility 2) gene encodes a mitochondrial protein localized in the photoreceptors outer segment. C3 (complement factor 3) and CFH (complement factor H) genes encode respectively the pivotal protein and the major inhibitor of the alternative pathway of the complement system.

Mathematical models have been progressively used to prepare algorithms capable of calculating the probability of progression of an individual toward the advanced stages of AMD.4–6 Former algorithms provided an original tool for identification of high-risk subjects among patients with early AMD. Though, their diffusion among Ophthalmologists has been limited, so far.

Development of a new algorithm

Starting from this experience, and based upon data coming from recent and consistent population-based studies, we have elaborated a mathematical model to predict the clinical risk of advanced AMD. Both genetic and epigenetic variables were combined, for a total amount of 13 parameters.

We divided the risk scores into 5 levels: I = low, II = mild, III = medium, IV = medium-high, V = high. The average risk of progression toward advanced stages of the disease, among the population over 60, is about 10%. People in the first level have a risk of late AMD lower than the average risk. People in the fourth and fifth levels have substantial chance of advanced disease, although only 3% belongs to these two categories.

The patients' risk level is calculated with software, originally designed for the AMDGeneticTest6 (Sooft Italia, Montegiorgio, Italy). The software follows a two-step procedure. First, it calculates the hypothetical pure 'genetic predisposition', based on genotype obtained from the collected sample (buccal cytobrushes). Then, after incorporating the OR of epigenetic parameters, it determines the overall 'clinical risk' of the patient of developing an advanced form of AMD within a certain period of time.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.